Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fritz Offner

Showing results (121-130 of 126) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 126 results.
Leukemia|July 22, 2018
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemiaRobert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
Nature Medicine|December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.
Leukemia|October 15, 2021
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myelomaArthur Bobin, Maéva Kyheng, Stéphanie Guidez, et al.
Blood|January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial updateMartin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
The Lancet. Oncology|June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
The Lancet. Oncology|September 16, 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
Pageof 13

Showing results (121-130 of 126) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 126 results.
Leukemia|July 22, 2018
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemiaRobert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
Nature Medicine|December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.
Leukemia|October 15, 2021
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myelomaArthur Bobin, Maéva Kyheng, Stéphanie Guidez, et al.
Blood|January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial updateMartin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
The Lancet. Oncology|June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
The Lancet. Oncology|September 16, 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
Pageof 13